Recommendations for the Treatment of Children With Burkitt's Lymphoma
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
View:
• Clinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment.
• \-
Locations
Other Locations
Burkina Faso
Hopital Yalgado Ouedraogo
RECRUITING
Ouagadougou
Democratic Republic of the Congo
Cliniques Universitaires de Kinshasa
RECRUITING
Kinshasa
Cliniques Universitaires de Lubumbashi (CUL)
RECRUITING
Lubumbashi
Madagascar
HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona
RECRUITING
Antananarivo
Mali
CHU Gabriel Touré (HGT)
RECRUITING
Bamako
Senegal
Hôpital Aristide Le Dantec
RECRUITING
Dakar
Contact Information
Primary
Chantal Ms BOUDA, Dr.
cgbouda@yahoo.fr
00(226)70 10 01 30
Backup
BRENDA MALLON, MSc PhD
brenda.mallon@gustaveroussy.fr
0033142115411
Time Frame
Start Date: 2020-11-01
Estimated Completion Date: 2030-12-31
Participants
Target number of participants: 1000
Treatments
All children with Burkitt lymphoma and in 2 units the addition of Rituximab
An amendment has been added to give 4 injections during induction treatments as in the study in adults, that is to say 1 injection on D1 and D6 of each induction treatment, COPM or COPADM depending on the risk group in two centers. It is an amendment of the therapeutic recommendations GFA LMB2019 which are the basis, the other centers will continue with this GFALMB2019 protocol as is
Related Therapeutic Areas
Sponsors
Leads: French Africa Pediatric Oncology Group